PMID- 23515495
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20151119
IS  - 1477-0903 (Electronic)
IS  - 0960-3271 (Linking)
VI  - 32
IP  - 10
DP  - 2013 Oct
TI  - Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as 
      prognostic markers of diabetic nephropathy.
PG  - 1089-96
LID - 10.1177/0960327112470274 [doi]
AB  - We aimed to find the relationship between serum transforming growth factor beta 
      1(TGF-beta(1)) and urinary monocyte chemoattractant protein-1 (MCP-1) throughout the 
      course of diabetic nephropathy (DN) and to assess the relationship between both 
      levels and other parameters of renal injury such as albumin/creatinine ratio and 
      estimated glomerular filtration rate (eGFR). Serum TGF-beta(1), urinary MCP-1, eGFR, 
      and glycosylated hemoglobin (HbA1c) were measured in 60 patients with type II 
      diabetes mellitus with different degrees of nephropathy (20 patients with 
      normoalbuminuria, 20 patients with microalbuminuria, and 20 patients with 
      macroalbuminuria) and compared with 20 matched healthy control subjects. Both the 
      levels of serum TGF-beta(1) and urinary MCP-1 were significantly higher in patients 
      with micro- and macroalbuminuria (137.8 +/- 69.5 and 329.25 +/- 41.46 ng/dl, 
      respectively, for TGF-beta(1) and 167.41 +/- 50.23 and 630.87 +/- 318.10 ng/g 
      creatinine, respectively, for MCP-1) compared with normoalbuminuric patients and 
      healthy controls (33.25 +/- 17.5 and 29.64 +/- 10.57 ng/dl, respectively, for 
      TGF-beta(1) and 63.85 +/- 21.15 and 61.50 +/- 24.81 ng/g creatinine, respectively, for 
      MCP-1; p < 0.001). There was a positive significant correlation between the 
      levels of serum TGF-beta(1) and those of urinary MCP-1 (r = 0.73, p < 0.001). Also, 
      serum TGF-beta(1) and urinary MCP-1 correlated positively with HbA1c (r = 0.49 and 
      0.55, respectively, p < 0.05 for both) and inversely with eGFR (r = -0.69 and 
      -0.60, respectively, p < 0.001 for both). We can conclude that serum TGF-beta(1) and 
      urinary MCP-1 can be used as the markers for detection of progression of DN. 
      Antagonizing TGF-beta(1) and MCP-1 might be helpful in attenuating the progression 
      of nephropathy in diabetic patients.
FAU - Shaker, O G
AU  - Shaker OG
AD  - 1Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, 
      Cairo University, Cairo, Egypt.
FAU - Sadik, N A H
AU  - Sadik NA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130320
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Biomarkers/blood/urine
MH  - Chemokine CCL2/*urine
MH  - Diabetes Mellitus, Type 2/blood/urine
MH  - Diabetic Nephropathies/blood/*diagnosis/urine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Transforming Growth Factor beta1/*blood
OTO - NOTNLM
OT  - Diabetic nephropathy
OT  - MCP-1
OT  - TGF-beta1
EDAT- 2013/03/22 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/03/22 06:00
PHST- 2013/03/22 06:00 [entrez]
PHST- 2013/03/22 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 0960327112470274 [pii]
AID - 10.1177/0960327112470274 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2013 Oct;32(10):1089-96. doi: 10.1177/0960327112470274. Epub 
      2013 Mar 20.